株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌領域における各種提携契約:契約条件・合意内容

Global Oncology Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 231905
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
癌領域における各種提携契約:契約条件・合意内容 Global Oncology Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年09月01日 ページ情報: 英文
概要

当レポートでは、2007年以降の癌領域における各種提携契約について調査分析し、癌関連の各種契約における近年の動向、大規模契約・大手医薬品事業者による契約の概要、契約タイプ・開発ステージ・技術タイプ・適応症の区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 癌関連の各種契約動向

  • イントロダクション
  • 長年にわたる提携
  • 大手製薬会社の契約活動
  • 癌領域で活動をしていない大手製薬会社
  • 癌関連の提携:取引タイプ別
  • 癌関連の提携:産業部門別
  • 癌関連の提携:開発段階別
  • 癌関連の提携:技術タイプ別
  • 癌関連の提携:適応症別
  • 平均取引条件

第3章 主要契約

  • イントロダクション
  • 主要取引:金額別
  • 大手製薬会社が関与している主要取引

第4章 大手医薬品企業による癌関連の各種契約

  • イントロダクション
  • 大手企業による提携取引の利用方法
  • 企業プロファイル

第5章 契約ディレクトリー

  • イントロダクション
  • 契約タイプ別
    • 資産購入
    • 譲渡
    • 大手医薬品企業のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同マーケティング
    • サービス契約
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売
    • 株式購入
    • 評価
    • 権利付与
    • ジョイントベンチャー
    • ライセンシング
    • 訴訟
    • ローン
    • 製造
    • マーケティング
    • 材料転移
    • オプション
    • プロモーション
    • 研究
    • ロイヤルティファイナンシング
    • 和解関連
    • スピンアウト
    • 供給
    • 技術移転
    • 解除
    • 保証
  • 開発ステージ別
    • 創薬
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • 申請登録
    • 市販
    • 配合
  • 技術タイプ別
    • 解析
    • 動物モデル
    • 抗体
    • アッセイ
    • バイオインフォマティクス
    • 生物学的化合物
    • バイオマーカー
    • 細胞治療
    • 臨床検査
    • 診断(コンパニオン)
    • デバイス
    • 診断
    • ディスカバリーツール
    • ドラッグデリバリー
    • 実現技術
    • 環境
    • 発生遺伝学
    • 機器
    • 設備
    • 遺伝子治療
    • ゲノミクス
    • イメージング
    • インプラント
    • 工業化学薬品
    • In Vitroモデル
    • ナノテクノロジー
    • 自然生産物
    • オリゴヌクレオチド
    • オーファンドラッグ
    • ペプチド
    • 個別化医療
    • 薬理ゲノミクス
    • プロセス
    • プロテオミクス
    • 放射線・化学療法、など

第6章 各種契約:適応症別

  • イントロダクション
  • 適応症別契約
    • 腫瘍学
    • 腺癌
    • 基底細胞癌
    • 胆管癌
    • 膀胱癌
    • 骨癌
    • 脳腫瘍
    • 乳癌
    • 子宮頸癌
    • 直腸癌
    • 子宮内膜
    • 食道癌
    • 胃癌
    • 頭頚部癌
    • カポジ肉腫
    • 腎臓癌
    • 白血病
    • 肝臓癌
    • 肺癌
    • リンパ腫、など

第7章 提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2201

‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’ report provides comprehensive understanding and unprecedented access to the oncology/cancer partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’ report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in Oncology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Oncology partnering agreement structure
  • Oncology partnering contract documents
  • Top Oncology deals by value
  • Most active Oncology dealmakers

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Oncology deals.

The report presents financial deal terms values for Oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Oncology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Oncology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Oncology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Oncology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Oncology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Oncology partnering deals by specific Oncology target announced since 2010. The chapter is organized by specific Oncology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Oncology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Oncology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Oncology technologies and products.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all oncology partnering deals announced since 2010 including financial terms where available including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope

‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’ is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’ includes:

  • Trends in oncology dealmaking in the biopharma industry since 2010
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 3,500 oncology deal records
  • The leading oncology deals by value since 2010

The report includes deals for the following indications: Oral mucositis, Cancer pain, Bone, Neuropathic, Muscular, Lymphoedema, Alopecia, Cachexia, Ulcers, Dysphagia, Tiredness, Weight loss, Nausea, Vomiting, Chemotherapy, Radiotherapy, Adenocarcinoma, Basal cell carcinoma, Bile duct cancer, Bladder cancer, Bone cancer, Brain cancer, Breast cancer, Cervical cancer, Colorectal cancer, Endometrial, Esophageal cancer, Gastric cancer, Head and neck cancer, Kaposi's sarcoma, Kidney cancer, Leukemia, Acute lymphoblastic leukemia, Acute myelogenous leukemia, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Liver cancer, Lung cancer, Small cell lung cancer, Non small cell lung cancer, Lymphoma, Hodgkin's lymphoma, Non Hodgkin's lymphoma, Melanoma, Mesothelioma, Metastases, Bone metastases, Multiple myeloma, Neuroblastoma, Non-melanoma skin cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Renal cell carcinoma, Sarcoma, Solid tumors, Testicular cancer, Thyroid cancer, plus other oncology indicatons.

In ‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’ report provides comprehensive access to available deals and contract documents for over 3,500 oncology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Oncology Partnering 2010-2016: Deal trends, players and financials’ provides the reader with the following key benefits:

  • In-depth understanding of oncology deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 3,500 actual oncology deals entered into by the world's biopharma companies
  • Detailed access to actual oncology contracts enter into by biopharma industries
  • Insight into the terms included in a oncology agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Oncology dealmaking

  • 2.1. Introduction
  • 2.2. Oncology partnering over the years
  • 2.3. Oncology partnering by deal type
  • 2.4. Oncology partnering by industry sector
  • 2.5. Oncology partnering by stage of development
  • 2.6. Oncology partnering by technology type
  • 2.7. Oncology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Oncology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Oncology partnering
  • 3.3. Oncology partnering headline values
  • 3.4. Oncology deal upfront payments
  • 3.5. Oncology deal milestone payments
  • 3.6. Oncology royalty rates

Chapter 4 - Leading Oncology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Oncology partnering
  • 4.3. List of most active dealmakers in Oncology
  • 4.4. Top Oncology deals by value

Chapter 5 - Oncology contract document directory

  • 5.1. Introduction
  • 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Oncology therapeutic target

Appendices

  • Appendix 1 - Directory of Oncology deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Oncology deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Oncology deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Oncology deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Oncology partnering since 2010
  • Figure 2: Oncology partnering by deal type since 2010
  • Figure 3: Oncology partnering by industry sector since 2010
  • Figure 4: Oncology partnering by stage of development since 2010
  • Figure 5: Oncology partnering by technology type since 2010
  • Figure 6: Oncology partnering by indication since 2010
  • Figure 7: Oncology deals with a headline value
  • Figure 8: Oncology deals with upfront payment values
  • Figure 9: Oncology deals with milestone payment
  • Figure 10: Oncology deals with royalty rates
  • Figure 11: Active Oncology dealmaking activity- 2010 to 2016
  • Figure 12: Top Oncology deals by value since 2010
Back to Top